Microbot Medical Expands U.S. Sales Footprint, Eyes 2027 Gross Margin Turnaround
Event summary
- Microbot Medical announced plans to expand U.S. sales footprint to 12 territories by year-end 2026, securing first California customer.
- Company hired three additional Area Sales Managers and one Regional Sales Director to support western U.S. expansion.
- Operating efficiencies, including a second manufacturing line, expected to drive positive gross margins in 2027.
- CE mark approval anticipated in late Q4 2026 or early Q1 2027, with potential expansions into Asia and Middle East markets.
The big picture
Microbot Medical's strategic focus on operational efficiencies and geographic expansion aligns with broader trends in the medical device industry toward cost optimization and market diversification. The company's push for positive gross margins in 2027 comes amid increasing competition in the endovascular robotics space, where precision and efficiency are key differentiators. The anticipated CE mark approval could further solidify its position in international markets, particularly in regions with high demand for advanced robotic surgical solutions.
What we're watching
- Regulatory Milestones
- Whether Microbot Medical can secure CE mark approval by early 2027, enabling international market expansion.
- Operational Execution
- The pace at which manufacturing efficiencies translate into positive gross margins in 2027.
- Commercial Adoption
- How early engagement with Value Analysis Committees accelerates hospital system adoption of the LIBERTY System.
Related topics